SVB Leerink Downgrades Blueprint Medicines to Underperform, Lowers Price Target to $43
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Andrew Berens downgrades Blueprint Medicines (NASDAQ:BPMC) from Market Perform to Underperform and lowers the price target from $48 to $43.
June 05, 2023 | 11:46 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Blueprint Medicines downgraded to Underperform by SVB Leerink, with a lowered price target of $43.
The downgrade from Market Perform to Underperform and the lowering of the price target from $48 to $43 by SVB Leerink analyst Andrew Berens indicate a negative outlook for Blueprint Medicines. This could lead to a short-term decrease in the stock price as investors may adjust their positions based on the new rating and price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100